Back to Search
Start Over
Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial
- Source :
- Diabetes Obesity & Metabolism, 9 (3), 394-407. Wiley
- Publication Year :
- 2007
-
Abstract
- Aim: Metformin is the 'drug-of-first-choice' in obese patients with type 2 diabetes mellitus (T2DM) due to its antihyperglycaemic and cardiovascular protective potentials. In non-obese patients with T2DM, insulin secretagogues are empirically used as first choice. In this investigator-initiated trial, we evaluated the effect of metformin vs. an insulin secretagogue, repaglinide on glycaemic regulation and markers of inflammation and insulin sensitivity in non-obese patients with T2DM. Methods: A single-centre, double-masked, double-dummy, crossover study during 2 x 4 months involved 96 non-obese (body mass index
- Subjects :
- Blood Glucose
Male
medicine.medical_specialty
endocrine system diseases
Endocrinology, Diabetes and Metabolism
medicine.medical_treatment
Type 2 diabetes
Endocrinology
Double-Blind Method
Piperidines
Diabetes mellitus
Internal medicine
Internal Medicine
medicine
Humans
Hypoglycemic Agents
Insulin
Prospective Studies
Glycated Hemoglobin
Cross-Over Studies
Adiponectin
C-Peptide
business.industry
Waist-Hip Ratio
Body Weight
Type 2 Diabetes Mellitus
nutritional and metabolic diseases
Middle Aged
medicine.disease
Repaglinide
Crossover study
Metformin
C-Reactive Protein
Diabetes Mellitus, Type 2
Hyperglycemia
Patient Compliance
Female
Carbamates
business
Biomarkers
medicine.drug
Subjects
Details
- ISSN :
- 14628902
- Volume :
- 9
- Issue :
- 3
- Database :
- OpenAIRE
- Journal :
- Diabetes, obesitymetabolism
- Accession number :
- edsair.doi.dedup.....c74fcab842a725acfc1480b9732d916d